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Hypertension is a common hereditary syndrome with unclear pathogenesis. Chromogranin A (Chga), which cat-
alyzes formation and cargo storage of regulated secretory granules in neuroendocrine cells, contributes to
blood pressure homeostasis centrally and peripherally. Elevated Chga occurs in spontaneously hypertensive
rat (SHR) adrenal glands and plasma, but central expression is unexplored. In this report, we measured SHR
and Wistar–Kyoto rat (control) Chga expression in central and peripheral nervous systems, and found Chga
protein to be decreased in the SHR brainstem, yet increased in the adrenal and the plasma. By re-sequencing,
we systematically identified five promoter, two coding and one 3′-untranslated region (3′-UTR) polymorphism
at the SHR (versus WKY or BN) Chga locus. Using HXB/BXH recombinant inbred (RI) strain linkage and correla-
tions, we demonstrated genetic determination of Chga expression in SHR, including a cis-quantitative trait loci
(QTLs) (i.e. at the Chga locus), and such expression influenced biochemical determinants of blood pressure, in-
cluding a cascade of catecholamine biosynthetic enzymes, catecholamines themselves and steroids.
Luciferase reporter assays demonstrated that the 3′-UTR polymorphism (which disrupts a microRNA miR-22
motif) and promoter polymorphisms altered gene expression consistent with the decline in SHR central Chga
expression. Coding region polymorphisms did not account for changes in Chga expression or function.
Thus, we hypothesized that the 3′-UTR and promoter mutations lead to dysregulation (diminution) of Chga in
brainstem cardiovascular control nuclei, ultimately contributing to the pathogenesis of hypertension in SHR.
Accordingly, we demonstrated that in vivo administration of miR-22 antagomir to SHR causes substantial
(∼18 mmHg) reductions in blood pressure, opening a novel therapeutic avenue for hypertension.
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INTRODUCTION
Hypertension is a common hereditary disorder whose pathogen-
esis remains largely obscure. Chromogranin A (CHGA ¼
human and Chga ¼ rodent) is a 48 kDa acidic protein crucial
for regulated secretory granule biogenesis as well as cargo traf-
ficking and storage in neurons, chromaffin cells and neuroendo-
crine tissues (1). CHGA is expressed in the central nervous
system as well as the periphery, in sites such as the adrenal
medulla, pancreatic islet cells and enteroendocrine cells (1).
CHGA also functions as a pro-hormone that yields bioactive
peptides capable of influencing a set of diverse traits, including
blood pressure (BP) and catecholamine secretion (catestatin
peptide) (2), insulin sensitivity and glucose homeostasis (pan-
creastatin peptide) (3) and vasodilation and inflammation
(vasostatin peptide) (4).
Chromogranin A was first implicated in the pathogenesis of
human essential (genetic) hypertension when heritable increases
in plasma CHGA were observed in hypertensive subjects (5–7).
Functional genetic variation at the human CHGA locus, in both
the proximal promoter (8,9) and the 3′-untranslated region
(3′-UTR) (9,10), is associated with essential hypertension
(8,10,11) as well as hypertensive end-organ damage (12), and
naturally occurring non-synonymous amino acid variation
within the catestatin (11,13) and pancreastatin (14,15) regions
change the potencies of these peptide hormones. Mahapatra
et al. (16) used targeted ablation of the Chga locus in the
mouse to demonstrate a direct relationship between Chga
genetic variation and hypertension in vivo. More recently, Vain-
gankar et al. (17) used this same Chga knockout model of hyper-
tension to create mouse lines with 0 (complete knockout), 1, 2, 3
or 4 copies of the Chga (or CHGA) gene per diploid organism.
The relationship between Chga copy number and BP was
U-shaped, wherein mice with 0 and 4 copies of Chga had the
highest BPs, whereas mice with 2 copies of Chga had the
lowest BP. Mice with one and three copies of Chga showed inter-
mediate BP values. It thus appeared that an optimal level of Chga
expression was necessary for normal BP homeostasis, with
either too much or too little expression leading to BP elevation.
The spontaneously hypertensive rat (SHR) and its control
strain, the Wistar–Kyoto rat (WKY), form the most widely
studied inbred animal model of genetic hypertension. Previous
studies reported overexpression of Chga in the plasma and the
adrenal gland of SHR versus WKY (18) and in the adrenal
gland of SHRSP versus WKY (19). Chga expression is widely
distributed in the brain (20,21), including the brainstem with
Figure 1. Chromogranin A (Chga) protein is elevated in peripheral (adrenal gland and plasma) but decreased central (brainstem) components of the nervous system
of SHR. An enzyme immunoassay determined that Chga protein was significantly increased in SHR adrenal gland [by 1.57-fold, (A)] and plasma [by 1.35-fold, (B)],
but decreased in SHR brainstem [by 0.83-fold, (C)]. Data were analyzed by an unpaired Student’s t-test, and presented as mean+ standard error.
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its cardiovascular control nuclei, such as the nucleus tractus soli-
tarii (NTS). Since Chga plays an important role in BP homeosta-
sis in both central and peripheral components of the nervous
system, we investigated Chga in the brainstem (central
nervous component) and adrenal gland (peripheral nervous com-
ponent) of the SHR. Since genetic variation at the Chga locus on
rat chromosome 6q32 (22) remains unexplored, we sought to
identify cis-acting polymorphisms within the SHR Chga locus
and determine their contributions to disease-mediating
changes in Chga expression or function. Finally, we tested the
hypothesis that a mutation within the Chga 3′-UTR which
alters a microRNA-binding motif, or the proximal promoter,
can lead to dysregulation of central Chga expression, ultimately
contributing to the pathogenesis of hypertension in the SHR.
RESULTS
Chromogranin A expression in SHR: peripheral elevation
versus central diminution
Chromogranin A (Chga) was measured in central (brainstem)
and peripheral (adrenal gland and plasma) components of the
nervous system in SHR and WKY rats (Fig. 1). Adrenal Chga
protein was increased 1.57-fold in SHR (3.32+ 0.23 ng/mg
adrenal protein) compared with WKY (2.12+ 0.19 ng/mg
adrenal protein; P ¼ 0.0008, Fig. 1A). Plasma Chga protein
was also increased 1.35-fold in SHR (1.45+ 0.12 ng/ml) com-
pared with WKY (1.08+ 0.06 ng/ml; P ¼ 0.014, Fig. 1B). In
contrast, brainstem Chga protein was decreased 0.83-fold in
SHR (0.65+ 0.05 ng/mg brainstem protein) compared with
WKY (0.78+ 0.03 ng/mg brainstem protein; P ¼ 0.029,
Fig. 1C).
Genomics: polymorphism discovery across the rat Chga
locus: SHR, WKY and BN strains
Targeted re-sequencing of the proximal promoter (2000 bp), 8
exons (including 5′- and 3′-UTRs) and intron/exon borders
(splice junctions) of the Chga locus in SHR versus WKY and
BN identified eight polymorphisms (Table 1, Fig. 2B). Five
SHR polymorphisms were identified within the proximal pro-
moter (21694 Ins/Del; A-1616T; 2753 Ins/Del; C-177T;
C-59T), one within Exon 5 [ + 6361 Ins/Del (Gln repeat:
SHR ¼ 12, WKY ¼ 20, BN ¼ 19)], one within Exon 6
[+8093 Ins/Del (Glu repeat: SHR ¼ 15, WKY ¼ 16, BN ¼
16)] and one within the 3′-UTR of Exon 8 (G + 11177T or
G + 174T with reference to the start of the 3′-UTR). The
3′-UTR variant G + 174T is found in NCBI dbSNP as
rs13449558. No polymorphisms were detected within regions
encoding bioactive peptides proteolytically derived from full-
length Chga protein, including vasostatin, catestatin or pan-
creastatin. Fourteen polymorphisms were identified within the
introns. These regions were not specific targets of re-sequencing
and were thus not systematically covered (gaps are present in
introns B, D, E and G; Fig. 2B). The single nucleotide poly-
morphism (SNP) within the 3′-UTR (G + 174T) occurred
within a region of the Chga locus that displayed high inter-
species conservation (Fig. 2A).
SHR, WKY and BN sequences were directly aligned with the
BN reference sequence at NCBI; the WKY and BN sequences
were identical in the promoter and 3′-UTR regions, but differed
at only one coding site (+6361 Ins/Del, Gln repeat) over the
entire re-sequenced range.
Recombinant inbred strains: evidence for a genetic role
of Chga in BP control in the SHR
Linkage analysis of adrenal Chga protein in HXB/BXH re-
combinant inbred (RI) strains revealed a peak (LOD ¼ 2.58,
P ¼ 0.00028) on rat chromosome 6q32 (22) directly above the
Chga locus (Fig. 2C). QTL peak location was confirmed by
2000 bootstraps. The LOD peak thus displayed suggestive
linkage (by 2000 permutation tests, 2.09,LOD,3.49; see
Fig. 2C legend), i.e. statistically expected to occur less than
once at random in the genome (23). SHR genotype was as-
sociated with increased adrenal Chga protein. By variance com-
ponents, we estimated that this cis-QTL accounted for 35% of
Table 1. Polymorphism discovery across the rat Chga locus
Polymorphism(s) Strain allele(s)
Location Domain Type BN (normotensive) WKY (normotensive) SHR (hypertensive)
21694 Ins/Del Promoter Ins/Del – – G
A-1616T Promoter SNP A A T
2753 Ins/Del Promoter Ins/Del 15 ‘A’ repeat 15 ‘A’ repeat 11 ‘A’ repeat
C-177T Promoter SNP C C T
C-59T Promoter SNP C C T
+6361 Ins/Del
(Gln repeat)
Exon 5 Ins/Del 15 tri-nucleotide ‘CAG’ repeats
(19 Gln repeat)
16 tri-nucleotide ‘CAG’ repeats
(20 Gln repeat)









SNP G G T
A list of polymorphismsdiscovered through resequencing of the Chga locus in the SHR, WKY and BN rat strains is presented. Polymorphisms are numbered according
to their position in relation to the mRNA cap site (transcriptional start site), which was designated as position ‘0’. Base pair position upstream of the cap site (i.e. in the
promoter) was numbered negatively in the descending order. Base pair position downstream of the cap site was numbered in the ascending order. Coding region
polymorphisms within exons 5 and 6 resulted in in-frame deletions of codons for glutamine and glutamic acid. Polymorphism G + 11177T in Exon 8 is also named
G + 174T, which refers to its position relative to the beginning of the 3′-UTR.
Ins/Del, insertion/deletion; SNP, single nucleotide polymorphism; 3′-UTR, 3′-untranlsated region; Gln, glutamine (amino acid); Glu, glutamic acid (amino acid).
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Figure 2. Chga locus on rat chromosome 6q32: Genomics. Inter-species sequence conservation, systematic polymorphism discovery across strains and cis-QTL.
(A) Inter-species conservation at the Chga locus. Conservation of the rat Chga locus across dog, rhesus, human and mouse genomes is presented. Regions
of the locus exceeding 70% conservation in a 100 bp sliding window analysis are colored either black (exons) or grey (upstream, intronic or downstream regions).
The 70% conservation threshold is indicated with a horizontal dashed line. (B) Polymorphisms discovered through re-sequencing of the rat Chga locus. Results in
the SHR,WKY and BN rat strainsare alsopresented. IntronicSNPs and SNPsdownstream of the final exon are not displayed. The Chga mRNAcap site (transcriptional
start site) was designated as position ‘0’. Base pair position upstream of the cap site (i.e. in the promoter) was numbered negatively in the descending order. Base pair
position downstream of the cap site in the exonic and intronic regions was numbered in ascending order. ORF, open reading frame; UTR, untranslated region. (C) The
Chga locus as a cis-QTL. Mapping of adrenal Chga protein (by immunoassay) as a quantitative trait in the HXB/BXH RI strains resulted in a significant meiotic re-
combination (linkage) peak (LOD ¼ 2.58, P ¼ 0.00028) on rat chromosome-6q32 over the Chga locus (shown with an arrow). 2000 bootstraps refined the position of
the QTL. The QTL accounted for 35% of trait variance. The SHR genotype was directionally associated with increased adrenal Chga protein. The x-axis is displayed
in genetic (recombination) units of centimorgans (cM). Genome wide-significance was approached by 2000 permutations, establishing thresholds for significant
(LRS ¼ 16.12, LOD ¼ 3.49) and suggestive (LRS ¼ 9.64, LOD ¼ 2.09) linkage.
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the variability in the adrenal Chga protein trait (i.e. 35%
heritability).
In the RI strains, adrenal Chga protein was directly correlated
with multiple adrenal biochemical determinants of BP, includ-
ing adrenal epinephrine (r ¼ 0.492, P ¼ 0.0051), norepineph-
rine (r ¼ 0.481, P ¼ 0.0064), dopamine (r ¼ 0.427, P ¼
0.0179), phenylethanolamine N-methyltransferase enzymatic
activity (Pnmt; r ¼ 0.628, P ¼ 0.00013), dopamine beta-
hydroxylase enzymatic activity (Dbh; r ¼ 0.510, P ¼ 0.0034),
chromogranin B protein (Chgb; r ¼ 0.546, P ¼ 0.0015) and cor-
ticosterone (r ¼ 0.636, P ¼ 0.00009) (Table 2). Paradoxically,
in the RI adrenal glands Chga mRNA abundance was inversely
correlated with Chga protein (r ¼ 20.417, P ¼ 0.0167), sug-
gesting derangement in the expected coupling between tran-
scription and translation for adrenal Chga (vide infra). Thus, a
genetic control of Chga biosynthesis in cis seems to originate a
cascade of tightly coupled catecholaminergic events in the RI
strains that impinge on an autonomic control of the circulation
(Supplementary Material, Fig. S1), with these elements: Chga
gene  Chga protein  Dbh  Norepinephrine  Pnmt
 Epinephrine.
Computational prediction of transcription factor binding
in the Chga promoter
The ConSite algorithm predicted differential binding of tran-
scription factors to the SHR and WKY Chga promoters in the
regions harboring polymorphisms (Table 3). Each of the five
polymorphisms was predicted to alter binding (as indicated by
difference in the ConSite score between SHR and WKY) of at
least one transcription factor: 21694 Ins/Del (Hand1, Pbx1),
A-1616T (Irf1, Sox17), 2753 Ins/Del (Foxd3), C-177T (E2f1,
Brachyury) and C-59T (Foxi1, Mycn, Rreb1).
Promoter-luciferase reporter assays: effect of Chga
promoter polymorphisms on transcription
Promoter-luciferase reporter assays demonstrated that the basal
transcriptional activity of the SHR Chga promoter was 0.83-fold
less than that of the WKY Chga promoter in rat PC12 (chromaf-
fin) cells (P , 0.05, Fig. 3A).
Since the basal promoter activity differed between strains, we
performed luciferase assays with co-transfection of expression
plasmids for the transcription factors predicted to differentially
bind to the polymorphic regions. In PC12 cells, two transcription
factors enhanced the expression of the WKY Chga promoter sig-
nificantly more than the SHR Chga promoter: Foxi1 at C-59T
(two-way ANOVA, P ¼ 0.024) and Brachyury at C-177T
(two-way ANOVA, P ¼ 0.010). The remaining transcription
factors (E2f1, Foxd3, Hand1, Irf1, Mycn, Pbx1, Rreb1 and
Sox17) did not interact significantly with the polymorphism
genotype (as determined by two-way ANOVA) in luciferase
experiments in PC12 cells (data not shown). None of the tran-
scription factors affected the expression of the pGL3-Basic
control vector.
Quantitative RT–PCR determined that Foxi1 and Brachyury
were not expressed in vivo in the SHR or WKY brainstem or the
adrenal gland (data not shown). We, therefore, confirmed
reduced basal expression of the SHR Chga promoter in a differ-
ent neuroendocrine cell type: human neuroblastoma SH-SY5Y
cells (Fig. 3A; 0.70-fold reduction, P , 0.05).
Computational prediction of microRNA binding
in the Chga 3′-UTR
The MicroInspector algorithm was used to predict differences
in hybridization free energy (and therefore the stability of
the microRNA–mRNA interaction) between microRNAs and
the SHR and WKY Chga 3′-UTRs in the region harboring the
G + 174T polymorphism. Two microRNAs, rno-miR-22 and
rno-miR-320, were predicted to form more stable duplexes
(and therefore have lower free energy when hybridized) with
the SHR Chga mRNA 3′-UTR than with the WKY Chga
mRNA 3′-UTR (Table 3).
3′-UTR-luciferase reporter assays: effect of the Chga
3′-UTR polymorphism on gene expression
Initial 3′-UTR-luciferase reporter assays showed that the basal
level of mRNA stability and translational efficiency conferred
by the SHR Chga 3′-UTR was 0.84-fold (216%) less than that
conferred by the WKY Chga 3′-UTR in PC12 cells (P ,
0.05). We then performed the luciferase assays with
co-transfection of synthetic precursors for the two microRNAs
predicted to hybridize the region harboring G + 174T. Micro-
RNA miR-22 displayed a significant interaction with the poly-
morphism genotype (two-way ANOVA; P ¼ 0.032), and
reduced the luciferase signal of the SHR 3′-UTR construct sig-
nificantly more than the WKY 3′-UTR construct (Fig. 3B).
MicroRNA miR-320 had no effect on SHR or WKY 3′-UTR con-
struct expression (Fig. 3B). Neither of the microRNA precursors
Table 2. Correlations of adrenal Chga protein with hypertensive disease
biochemical phenotypes in the RI strains
Hypertensive disease trait
correlated with adrenal Chga

































Analysis of the HXB/BXH RI strains identified significant parametric (Pearson)
correlations (∗P , 0.05) of adrenal Chga protein with multiple adrenal
biochemical regulators of blood pressure.
Pnmt (phenylethanolamine N-methyltransferase), Dbh (dopamine
beta-hydroxylase), Chgb (chromogranin B).
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affected the pGL3-Promoter control vector (Fig. 3B). Poly-
morphism G + 174T was predicted to alter the conformation
and free energy of binding between SHR Chga 3′-UTR and
miR-22 (Supplementary Material, Fig. S2). RT–PCR analysis
determined that miR-22 was expressed in vivo in SHR and
WKY brainstems and adrenal glands (vide infra, under mRNAs).
Computational genome-wide prediction of miR-22 targets
using the TargetScan algorithm identified 343 potential tran-
scripts, with binding scores (total context + score) ranging
from 20.70 to 20.02 (Supplementary Material, Table S2).
Computational analysis of secondary structural changes
in Chga protein
Inter-species conservation (across mammals: Homo sapiens,
Macaca mulatta, Bos taurus, Canis familiaris, Equus caballus,
Mus musculus, Rattus norvegicus) of the regions harboring the
glutamine (+6361 Ins/Del, Exon 5) and glutamic acid (+8093
Ins/Del, Exon 6) Ins/Del polymorphisms was determined: the
glutamine Ins/Del was present only in rodents (rat and mouse),
whereas the glutamic acid Ins/Del was present only in rat.
Since human Chga protein may assume a coiled-coil structure
(24), and coiled coils usually contain a repeated pattern of hydro-
phobic and polar residues, we computed the effect of the glutam-
ine (polar residue) and glutamic acid Ins/Dels on the ability of
SHR and WKY Chga proteins to assume coiled-coil structures
(Fig. 4A). The glutamine Ins/Del was predicted to increase the
probability of SHR protein to form a coiled coil by 25%, yet
decrease the number of residues involved in a coiled-coil
segment by eight. The glutamic acid Ins/Del was predicted to
have no effect on the coiled-coil structure of SHR Chga protein.
EAP chimeric reporter assays: effect of Chga coding
polymorphisms on regulated secretion
Embryonic alkaline phosphatase (EAP) secretion and activity
assays were performed with SHR and WKY Chga cDNA-EAP
reporter constructs to determine whether the glutamine Ins/Del
(predicted to increase coiled-coil probability by 25% and de-
crease the number of residues within a coiled coil by 8) affected
trafficking and secretion of Chga protein by the regulated secre-
tory pathway. Relative secretion (Rs) is defined as the fraction of
total EAP activity that is found in the supernatant after stimula-
tion: Rs ¼ (EAP activity in supernatant)/(EAP activity in
supernatant + EAP activity in lysate). Sorting index (SI) is
defined as the difference between Rs of barium (strong exocyt-
osis stimulation) and calcium (control)-treated cells, normalized
by the Rs of calcium-treated cells: SI ¼ (Rsbarium–Rscalcium)/
Rscalcium. No difference was detected in Rs or SI of SHR
(2.57+ 0.26) and WKY (2.49+ 0.22) Chga proteins (P ¼
0.84, Fig. 4B).
RNA transcript abundance: quantitative RT–PCR
qRT–PCR probed in vivo mRNA and microRNA expression
profiles in central (brainstem) and peripheral (adrenal gland)
components of the nervous system in the SHR. We probed the
following transcripts: chromogranin A (Chga); solute carrier
family 18, member 1 (Slc18a1 or Vmat1; an amine transporter
located in the membrane of catecholamine storage vesicles);
tyrosine hydroxylase (Th; the rate-limiting enzyme in catechol-
amine biosynthesis); cAMP-responsive element-binding
protein 1 [Creb1; transcription factor that regulates the expres-
sion of Chga (1), Slc18a1/Vmat1 (25) and Th (26,27)] and
miR-22. In the brainstem, Chga (+1.3-fold, P ¼ 0.01),
Slc18a1/Vmat1 (+8.8-fold, P , 0.0001), Th (+1.3-fold, P ¼
0.037) and Creb1 (+1.6-fold, P , 0.001) mRNAs were ele-
vated in the SHR, whereas miR-22 transcript was unchanged
(Fig. 5A). In the adrenal gland, Chga [+1.3-fold, P ¼ 0.055
(marginally significant)], Slc18a1/Vmat1 (+1.5-fold, P ¼
0.021), Th (+1.8-fold, P ¼ 0.032) and Creb1 (+1.6-fold, P ¼
0.026) mRNAs were elevated in the SHR, whereas miR-22 tran-
script showed no change (Fig. 5B). The marginally significant
elevation of Chga mRNA in the adrenal gland we observed
(P ¼ 0.055) is consistent with previous reports of a significant
elevation of Chga mRNA in the SHR adrenal gland (18).
Table 3. Computational prediction of transcription factor and microRNA binding to polymorphic regions within the Chga locus
Polymorphism Location in gene Predicted TF WKY ConSite score SHR ConSite score
21694 Ins/Del Promoter Hand1 (MA0092, +) 5.828 6.090
Pbx1 (MA0070, 2) 8.101 7.716
A-1616T Promoter Irf1 (MA0050, 2) 7.822 n/a
Sox17 (MA0078, +) 7.255 n/a
2753 Ins/Del Promoter Foxd3 (MA0041, 2) 9.407 8.520
C-177T Promoter E2f1 (MA0024, 2) 6.381 n/a
Brachyury (MA0009, 2) 7.749 12.466
C-59T Promoter Foxi1 (MA0042, +) n/a 8.300
Mycn (MA0104, 2) 4.675 n/a
Rreb1 (MA0073, 2) 8.543 9.205
Polymorphism Location in gene Predicted microRNA WKY free energy SHR free energy
G + 174T 3′UTR rno-miR-22 222.9 kcal/mol 223.71 kcal/mol
rno-miR-320 n/a 222.6 kcal/mol
The ConSite algorithm predicted differential binding (indicated by difference in score) of 10 transcription factors to regions within the Chga promoter containing the
five polymorphisms discovered through resequencing. Transcription factor JASPAR accession number and DNA strand binding orientation (+ or 2) are listed in
parentheses following the transcription factor symbol. The MicroInspector tool predicted differential stability of hybridization (indicated by difference in free energy)
between two microRNAs and the region of the Chga mRNA 3′-UTR containing the G + 174T polymorphism. A lower free energy indicates a more stable interaction
between microRNA and mRNA.
TF, transcription factor; n/a, not applicable (no binding or hybridization was predicted).
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Inhibition of microRNA-22 in vivo: BP measurement
and biochemical assays
Administration of miR-22 antagomir (via IP injection; dose of
25 mg/kg every other day) resulted in an 11 mmHg reduction
of systolic blood pressure (SBP) (177 mmHg on Day 1 to
166 mmHg on Day 9) (Fig. 6A) and a 15 mmHg reduction of dia-
stolic blood pressure (DBP) (126 mmHg on Day 1, to 111 mmHg
on Day 9) (Fig. 6B) in the SHR after 9 days (four doses). The
initial dose of antagomir resulted in rapid (within 48 h) and sub-
stantial 18 mmHg decreases in both SBP (177 mmHg on Day
1, to 159 mmHg on Day 3) and DBP (126 mmHg on Day 1 to
108 mmHg on Day 3). Treatment with miR-22 antagomir sig-
nificantly reduced both SBP (F ¼ 74.5, P ¼ 0.00005) and
DBP (F ¼ 15.3, P ¼ 0.0002) compared with negative control
oligonucleotide. MicroRNA-22 antagomir administration had
Figure 3. Functional polymorphism (luciferase reporter) assays: SHR promoter
and 3′-UTR polymorphisms decrease Chga gene expression in cultured cells.
Luciferase reporter assays were used to determine whether polymorphisms
within the SHR Chga promoter and 3′-UTR affect gene expression. Note that
WKY and BN promoter and 3′-UTR sequences are identical. (A) Chga promoter.
The basal transcriptional activity of the SHR Chga promoter was less than that
of the WKY Chga promoter in both rat pheochromocytoma PC12 cells and
human neuroblastoma SH-SY5Y cells (∗P , 0.05 versus WKY basal expres-
sion). (B) Chga 3′-UTR. In PC12 cells, co-transfection of synthetic precursors
for microRNAs predicted to hybridize differentially to the polymorphic region
in the Chga 3′-UTR revealed a significant (two-way ANOVA) genotype-
by-microRNA interaction for miR-22. Data are presented as mean+ standard
error. ∗P , 0.05 versus WKY-negative control.+P , 0.05 versus SHR-negative
control.
Figure 4. Effect of coding region polymorphisms. (A) Chga protein coiled-coil
structure. Since the human CHGA protein exhibits a coiled-coil structure, the
probability of the WKY (top) and SHR (bottom) Chga proteins to also assume
a coiled-coil structure was computed with the COILS algorithm. The probability
of coiled-coil structure is presented as a function of amino acid residue position in
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no differential effect on heart rate (HR) (F ¼ 0.956, P ¼ 0.331)
(Fig. 6C).
We measured Chga protein and mRNA abundance in the
brainstem, adrenal gland and plasma in SHR after 9 days of the
administration of miR-22 antagomir or negative control
(Table 4). Brainstem Chga protein increased 1.33-fold
(+33%, P ¼ 0.027), whereas adrenal Chga protein decreased
0.52-fold (248%, P ¼ 0.01), and plasma Chga protein did not
change. Neither brainstem nor adrenal Chga mRNA abundance
changed after miR-22 antagomir administration.
A blood plasma chemistry panel revealed no adverse effects of
in vivo miR-22 antagomir treatment on carbohydrate metabol-
ism (glucose), kidney function [blood urea nitrogen (BUN), cre-
atinine], electrolytes (sodium, phosphorus) or liver function
(alkaline phosphatase, albumin, total protein, globulin, total bili-
rubin) in the SHR (Table 5). Treatment with miR-22 antagomir
actually resulted in modest declines in hepatocyte glutamic
pyruvic transaminase (control: 68+ 5 U/l, antagomir: 55+
2 U/l; P ¼ 0.02) and pancreatic amylase (control: 846+17 U/l,
antagomir: 729+23 U/l; P ¼ 0.0008).
DISCUSSION
Central versus peripheral expression of chromogranin A
Chromogranin A plays a necessary role in the formation and
cargo storage of regulated secretory granules in neuroendocrine
cells (16). In the central nervous system (brainstem), neuronal
Chga-granules store catecholamines and may release these neu-
rotransmitters to regulate sympathetic outflow to the periphery
(11). We observed a 0.83-fold decrease in Chga protein in the
brainstem of SHR (Fig. 1C), likely leading to impaired or
reduced ability of SHR to store catecholamines in this brain
region vital to BP regulation. In fact, it was previously shown
that the norepinephrine content was decreased in the NTS (in
the medulla oblongata of the brainstem) of SHR versus WKY
(28), and in the medulla oblongata (brainstem) of SHRSP
versus WKY (29).
In adrenal medullary chromaffin cells of the peripheral
nervous system, Chga-granules store catecholamines and
release these endocrine hormones to stimulate and support
Figure 5. Endogenous gene expression by quantitative RT–PCR: The measure-
ment of transcript abundance in central and peripheral tissues of the SHR nervous
system. We performed quantitative RT–PCR to determine in vivo mRNA and
microRNA expression profiles in central (brainstem) and peripheral (adrenal
gland) components of the SHR nervous system for the following transcripts:
Chga, Slc18a1/Vmat1, Th, Creb1 and miR-22. Data were normalized to
beta-actin in the same sample, and analyzed with an unpaired Student’s t-test,
and presented as mean+ standard error. ∗P , 0.05 versus WKY (significant);
+P ¼ 0.055 versus WKY (marginally significant). Normalization of miR-22
abundance in the brainstem by a snoRNA (SNORD61) instead of beta-actin
resulted in 0.76-fold (P , 0.05) decreased miR-22 in SHR compared with
WKY; beta-actin normalization resulted in no difference. Normalization of
miR-22 abundance in the adrenal gland by SNORD61 was consistent with
beta-actin normalization, resulting in no difference between SHR and WKY.
the Chga protein. The glutamine repeat polymorphism was predicted to increase
the probability of SHR protein to assume a coiled-coil structure by 25%, yet
decrease the number of residues involved in a coiled-coil segment by eight.
The glutamic acid polymorphism was predicted to have no effect on the coiled-
coil structure of SHR Chga protein. WKY and BN sequences at Chga, though
indentical in the promoter, 3′-UTR, and oligo-Glu repeat, differed at one
coding site, the oligo-Gln repeat (+6361 Ins/Del, Gln repeat, Table 1), where
SHR displayed (Gln)12, with WKY at (Gln)16 and BN at (Gln)15. (B) Chimeric
(in-frame) reporter assays: SHR coding polymorphisms do not affect trafficking
and secretion of Chga protein into the regulated secretory pathway. EAP secre-
tion and activity assays were performed with SHR and WKY Chga in-frame
cDNA/EAP reporter constructs to determine whether SHR coding polymorph-
isms affected trafficking and secretion of Chga protein in the regulated secretory
pathway. The secreted embryonic alkaline phosphatase construct, which enters
the constitutive secretory pathway, was a negative control for the SHR and
WKY Chga constructs. The human construct, which has previously been tested
and validated (56), served as a positive control for correct trafficking and regu-
lated secretion of Chga. No difference was detected in the Rs of SHR or WKY
constructs to either barium (a potent stimulus of regulated secretion) or
calcium (negative control for barium) stimulation (data not shown). Rs ¼
(EAP activity in supernatant)/(EAP activity in supernatant + EAP activity in
cell lysate). No difference was detected in the sorting index of SHR (2.57+
0.26) and WKY (2.49+0.22) Chga protein (P ¼ 0.84). Sorting index (SI) ¼
(Rsbarium – Rscalcium)/Rscalcium. Data were analyzed with an unpaired Student’s
t-test, and presented as mean+ standard error.
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sympathetic activity throughout the periphery. We observed
1.57-fold elevation of Chga protein in the adrenal gland of
SHR (Fig. 1A), which is consistent with previous reports of
elevated adrenal Chga protein in SHR versus WKY (18,19).
Increased abundance of Chga suggests that the SHR
adrenal gland has acquired additional capacity to store cate-
cholamines in regulated secretory granules. Indeed, elevated
adrenal norepinephrine in SHR versus WKY (18,30) and in
SHRSP versus WKY (19,30) has been reported in the litera-
ture. We also observed a 1.35-fold elevation of Chga
protein in the plasma of SHR (Fig. 1B), consistent with pre-
vious investigations of SHR versus WKY (18), which in-
dicates that peripheral sympathetic activity is enhanced in
the SHR.
Catecholamines, such as norepinephrine, have quite different,
indeed opposite effects on BP (31) when administered peripher-
ally (e.g. pressor/hypertensive effects when given intravenous-
ly) versus centrally (e.g. depressor/hypotensive effects when
given within/onto the NTS in the brainstem, likely mediated
bya2-adrenergic receptors) (32). Since Chga triggers the forma-
tion of catecholamine storage vesicles in the regulated pathway
(16) and binds catecholamines within the soluble core of such
vesicles (33), changes in catecholamine storage/availability
mediated by variation in Chga abundance in the SHR would be
predicted to have opposite consequences in central and periph-
eral compartments, as follows:  Central Chga   Central
catecholamines   BP;  Peripheral Chga   Peripheral
catecholamines   BP. Indeed, the catecholamine
release-inhibitory catestatin fragment of Chga exhibits oppo-
site peripheral versus central effects on BP: decreasing BP
when given intravenously (16), yet increasing BP when given
centrally (34).
Thus, the changes we observed in SHR Chga expression
( Central   Peripheral) would each be expected to yield
increases in BP. The question now turned to whether and how
Chga genetic variation in cis might achieve such effects.
Figure 6. MicroRNA-22 inhibition in vivo and conservation across species. (A–C) MicroRNA-22 inhibition in vivo: miR-22 antagomir decreases blood pressure in
the SHR. SHR were administered either miR-22 antagomir (n ¼ 10) or scrambled sequence negative control (n ¼ 9) via IP injection. Animals received IP doses
(at 25 mg/kg) on Days 1, 3, 5, and 7. MicroRNA-22 antagomir treatment significantly reduced both systolic (A) and diastolic (B) blood pressure in the SHR
(versus negative control group). Antagomir administration had substantial acute (18 mmHg reduction within 48 h) and sustained (13 mmHg reduction after
9 days) effects on blood pressure. MicroRNA-22 antagomir administration had no effect on heart rate (C). Data were analyzed with a linear mixed effects model
in SPSS. (D) Inter-species conservation of the miR-22 binding site in the 3′-UTR region of the rat Chga locus. The predicted site of miR-22 hybridization (as it
would occur in transcribed Chga mRNA) is underlined in the DNA sequence of the Chga locus. Location of the SHR/WKY G + 174T SNP (SHR allele ¼ ‘T’;
WKY allele ¼ ‘G’) is shown in bold text. Individual bases conserved across human, rat and mouse are indicated with ∗. The miR-22 binding site is well conserved,
indicating its likelihood of miR-22 regulation of CHGA in humans. Note that WKY and BN 3′-UTR sequences are identical.
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BP is influenced by genetic cis-regulation of the
Chga locus in the SHR
Using RI strain meiotic linkage, we first established that adrenal
Chga protein in the SHR was under substantial genetic regula-
tion in cis at the Chga locus (Fig. 2C), and then demonstrated
that these genetically determined levels of Chga significantly
predict biochemical regulators of BP, including catecholamines,
catecholamine synthetic enzymes, catecholamine storage pro-
teins and steroid hormones (Table 2), suggesting that cis-
regulation of Chga expression (Fig. 2C) controls a sequential
pathway of catecholaminergic events (Supplementary Material,
Fig. S1). While the RI linkage and cis-QTL data are based on
adrenal expression, additional brainstem-specific linkage ana-
lysis would further support genetic regulation of the Chga
locus in cis, and elucidate the role of tissue-specific regulation.
Pertinent to our results, in a previous rat genetic F2 intercross
of a salt-sensitive hypertension model (BN/SsNHsdxSS/
JrHsdMcwi; as described in (35), and archived at the Rat
Genome Database ,http://rgd.mcw.edu.), the Chga locus
[on rat chromosome 6q22; (22)] lay within the linkage confi-
dence interval for mean arterial pressure, as BP-QTL-211
(LOD ¼ 3.66).
Proximal promoter polymorphisms decrease SHR
Chga promoter activity
Next, we sought to identify cis-acting Chga polymorphisms that
might contribute to differential expression of Chga protein and,
therefore, regulation of BP. We re-sequenced the Chga locus and
demonstrated that the C-59T and C-177T polymorphisms dis-
rupted binding sites for Foxi1 and Brachyury, respectively, con-
sistent with the decreased basal transcriptional activity of the
SHR Chga promoter. However, since neither Foxi1 nor Brachy-
ury mRNA transcripts were expressed in SHR or WKY brain-
stem or adrenal gland in vivo, we confirmed the reduced basal
activity of the SHR promoter in a different cell type,
SH-SY5Y (Fig. 3A). Foxi1 was expressed endogenously in
PC12 cells (25) but not in SH-SY5Y cells (NCBI Gene Expres-
sion Omnibus Dataset, GDS1548; http://www.ncbi.nlm.nih.
gov/sites/geo). The endogenous expression of Brachyury in
PC12 cells is unknown; however, Brachyury is not expressed en-
dogenously in SH-SY5Y cells (NCBI Gene Expression
Omnibus Dataset, GDS1548). Perhaps Foxi1 and Brachyury
do not contribute to the reduced basal activity of the SHR pro-
moter. Additional experiments may elucidate the mechanism
whereby functional SNPs within the SHR promoter reduce
basal transcriptional activity.
3′-UTR polymorphism decreases SHR Chga gene expression
The observation that RI adrenal gland Chga mRNA abundance
was inversely correlated with Chga protein (r ¼ 20.366, P ¼
0.046), suggested derangement in the expected coupling
between transcription and translation for Chga; since microRNA
binding to the 3′-UTR can control mRNA translation, we
explored the 3′-UTR sequences of Chga. The G + 174T muta-
tion was demonstrated to lie within a miR-22 binding site and
provide a plausible mechanism to explain the decreased
mRNA translational efficiency (and, therefore, decreased gene
expression) conferred by the SHR 3′-UTR (Fig. 3B). We
probed the expression of miR-22 in vivo and determined that it
was indeed expressed in both SHR and WKY brainstems as
well as adrenal glands (Fig. 5).
Chga coding region polymorphisms lack detectable
effects on secretory trafficking
Even though the glutamine Ins/Del was computationally pre-
dicted to change the coiled-coil structure of SHR Chga protein
(Fig. 4A), the fact that the glutamine repeat region existed only
in rodents and was not conserved across species (rat, mouse,
dog, rhesus and human) suggested that this region is not
Table 4. Effect of miR-22 antagomir treatment on Chga mRNA and protein
abundance in the SHR









Chga protein 1.33-fold (P ¼ 0.027) 0.52-fold (P ¼ 0.01) No change
Chga mRNA No change No change Not applicable
We measured Chga protein and Chga mRNA transcript abundance fold change in
SHR after 9 days of treatment with miRNA-22 antagomir or negative control.
Statistically significant P-values (,0.05) are shown in parentheses following
fold-change values. Fold change .1 indicates increased abundance in the
miR-22 antagomir treatment group; fold change ,1 indicates decreased
abundance in the miR-22 antagomir treatment group. Data were analyzed with
Student’s t-test.
Table 5. Chemistry panel results indicate no adverse effects of in vivo miR-22
antagomir treatment








Glucose (mg/dl) 189+5 196+3 0.23
Kidney function
BUN (mg/dl) 20+1 20+1 0.70
Creatinine (mg/dl) 0.2+0.01 0.2+0.02 0.34
Electrolytes
Sodium (mEq/l) 162+1 164+1 0.33





Albumin (g/dl) 4.7+0.1 4.7+0.1 0.89
SGPT (ALT) (U/l) 68+5 55+2 0.02∗
Total protein (g/dl) 5.8+0.1 5.8+0.1 0.46
Globulin (g/dl) 1.1+0.1 1.1+0.1 0.75
Total bilirubin (mg/dl) 0.2+0.01 0.2+0.02 0.34
Pancreas function
Amylase (U/l) 846+17 729+23 0.0008∗
A standard chemistry panel was performed on plasma from SHR treated with
miR-22 antagomir or negative control. Data were analyzed with Student’s t-test.
Statistically significant differences (P , 0.05) are indicated with ∗.
BUN, blood urea nitrogen; SGPT, serum glutamic pyruvic transaminase.
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crucial for Chga protein function. Indeed, EAP secretion and ac-
tivity assays confirmed that the glutamine deletions in SHR Chga
did not affect the trafficking or regulated release of the protein
(Fig. 4B).
Potential contribution of unknown or uncharacterized
polymorphisms
It was conceivable that functional transcriptional elements were
present upstream of the 2-kb proximal promoter region that
was re-sequenced in SHR and WKY. For example, the highly
conserved region 4 kb upstream of Chga exon-1 (Fig. 2A)
might function in transcriptional regulation. The sequence of
this region in the SHR and WKY strains remains unknown,
and our promoter-luciferase reporter constructs did not contain
or test the function of this upstream region. Nor was our study
designed to detect enhancer elements located long distances
from the Chga locus.
The effects of the 14 intronic polymorphisms were not exam-
ined. Of interest were polymorphisms A + 1113G within
Intron-B and T + 3961C within Intron-C, which occur within
regions of high inter-species conservation (Fig. 2A). We did
not target the entire introns for re-sequencing, and additional
or unknown functional polymorphisms might exist within
un-sequenced intronic regions.
Chga as a contributor to the pathogenesis of hypertension
in the SHR
We present the hypothesis that the 3′-UTR and promoter Chga
polymorphisms contribute to reduced Chga protein expression
in the brainstem of SHR, ultimately eventuating in development
of systemic hypertension (Fig. 7). We are not the first to hypothe-
size involvement of the brainstem in the pathogenesis of hyper-
tension in the SHR. Takami et al. (29) hypothesized that since
norepinephrine was decreased in the NTS in the medulla oblon-
gata of SHR, and since norepinephrine has an inhibitory effect in
the NTS on systemic BP elevation, ‘the suppression of negative
feedback due to a decrease in the activity of inhibitory neurons in
the medulla oblongata appears to be involved in the development
and progression’ of hypertension in the SHR (29); we build upon
the conclusions of Takami et al. (29) to include a genetic basis at
the Chga locus.
We therefore propose that the 3′-UTR and promoter Chga
polymorphisms lead to reduced Chga protein expression in the
SHR brainstem (Fig. 1C) via reduced mRNA transcription
(Fig. 3A) and altered binding of miR-22 (Fig. 3B), and conse-
quently reduced norepinephrine levels (28,29). It is likely that
reduced mRNA translation also contributes to reduced Chga
protein level. Since norepinephrine acts to reduce BP in the
brainstem (especially in the NTS of the medulla oblongata), re-
duction of norepinephrine in this region should then lead to
enhanced central sympathetic outflow to the periphery. Aberrant
storage and secretion of norepinephrine in the brainstem might
also affect baroreceptor function. Elevation of adrenal Chga
protein (Fig. 1A), adrenal Chga (18), Slc18a1, Th, and Creb1
mRNAs (Fig. 5), adrenal norepinephrine (18,19,30) and
plasma Chga protein (Fig. 1B) support the notion of increased
peripheral sympathetic stimulation and activity. Indeed, Chga ex-
pression is up-regulated by ganglionic sympathetic transmitters,
such as nicotinic–cholinergic agonists and neuropeptides (1),
and previous studies have reported enhanced peripheral sympa-
thetic activity in the SHR (18,36–38). The ultimate effect of
the 3′-UTR and promoter Chga polymorphisms would then be
elevated BP (hypertension) stemming from increased central
sympathetic outflow from the brainstem.
Although the Chga 3′-UTR and promoter SNPs are expected
to be operative in the adrenal gland as well, enhanced central
sympathetic outflow arising from the brainstem is likely to
stimulate adrenal Chga gene expression, resulting in our obser-
vations of increased Chga adrenal mRNA and protein. Lack of
cis-regulation for adrenal Chga mRNA in the RI strains supports
a primary role for central control of adrenal Chga mRNA and
protein expression. In addition, elevated BP is proposed to
provide a negative feedback to the central nervous system,
leading to compensatory increases in Chga, Slc18a1, Creb1
and Th mRNAs in the brainstem (Fig. 5A). Apparently, the com-
pensatory signals are not strong enough to overcome the com-
bined pro-hypertensive effect of both the promoter and
3′-UTR Chga SNPs, resulting in dominance of the primary
over compensatory effects. The main effect of SNPs in the
SHR promoter is to reduce transcriptional activity (Fig. 3A).
Elucidation of the temporal characteristics of Chga, Slc18a1,
Creb1 and Th transcript alterations in the brainstem would
prompt additional investigation. Normalization of miR-22
abundance in the brainstem by a snoRNA (SNORD61) instead
of beta-actin resulted in 0.76-fold (P , 0.05) decreased
miR-22 in SHR compared with WKY; beta-actin normalization
resulted in no difference. In either case, the decreased level of
Chga protein in the SHR brainstem suggests that the effect of
the G + 174T 3′-UTR SNP is dominant over the effect of
miR-22 expression. Normalization of miR-22 abundance in
the adrenal gland by SNORD61 was consistent with beta-actin
normalization, resulting in no difference between SHR and
WKY.
Seemingly paradoxical differences in effects of SNPs on gene
expression in cell culture and in vivo are frequently observed in
complex trait genetics. Here, we observe an effect of the Chga
3′-UTR and promoter SNPs to reduce gene expression in cell
culture, yet Chga protein is overexpressed in the SHR adrenal
gland and the plasma. Only through consideration of central
(brainstem) versus peripheral (adrenal gland and plasma) Chga
expression were we able to reconcile these seemingly opposing
observations. This concept of central versus peripheral actions
and the expression of physiological pathways and their candidate
genes loom large in the complex trait genetics literature. We
have already noted the opposing effects of catecholamines on
BP in the central versus peripheral pathways (31). Other trans-
mitter systems have opposing central and peripheral effects on
BP. In humans, genetic variation in the neuropeptide Y receptor
type 1 (NPY1R) promoter and 3′-UTR that decreased gene ex-
pression in cell culture predicted increased BP in vivo (39),
and genetic variation in the human dopamine beta-hydroxylase
(DBH) promoter had directionally opposite effects on gene ex-
pression in cell culture and on plasma DBH activity, urine epi-
nephrine and BP in vivo (40). Similar effects in the central and
peripheral nervous systems have also been reported for poly-
morphisms in human peptide YY (PYY) and obesity (41).
In each case (NPY1R, DBH and PYY), the deleterious effects
of specific genetic determinants were explained through
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consideration of their reciprocal effects in the central and periph-
eral nervous systems.
Administration of miR-22 antagomir in vivo leads to a rapid
yet prolonged decrease in SBP and DBP in the SHR
(18 mmHg reduction with 48 h; sustained reduction after 9
days), without change in the HR or the reflex tachycardia re-
sponse (Fig. 6). Such striking and effective reductions in BP
further implicate the Chga locus in the pathogenesis of hyperten-
sion in the SHR, and suggest therapeutic applications for miR-22
antagomir. Computational, genome-wide analysis identified
additional targets potentially regulated by miR-22 (Supplemen-
tary Material, Table S2), though the exact number of genes regu-
lated in vivo is unknown. Undoubtedly, miR-22 regulates the
expression of at least some other genes, and the contribution of
these additional effects to BP homeostasis remains unexplored.
Base pair hybridization between miR-22 and the SHR or
WKY Chga 3′-UTR is imperfect (i.e. it contains two mismatches
in canonical Watson–Crick pairing; Supplementary Material,
Figure S2), suggesting that the mechanism whereby miR-22
decreases Chga protein expression involves translational repres-
sion (perhaps by steric hindrance) rather than degradation of
target mRNA (which would be expected only for perfect
match microRNA:mRNA base pairing) (42). Our observation
in the brainstem of increased Chga protein but unchanged
Chga mRNA after miR-22 antagomir treatment is consistent
with this mechanism of translational repression. Increased
Chga protein abundance in the brainstem after miR-22 antago-
mir administration is consistent with inhibition of miR-22 in
this tissue; however, additional studies could reveal more exten-
sive patterns of tissue and cell type-specific uptake of miR-22
antagomir in the SHR after IP administration. It has previously
been reported that a microRNA antagomir administered intra-
venously through the tail vein in the mouse penetrated the
brain to exert its regulatory effects (43). It was also conceivable
that increased Chga protein in the brainstem resulted, in part,
from feedback of a primary effect of antagomir in the periphery
(adrenal gland); however, reduced Chga adrenal protein after
antagomir treatment seems incompatible with this idea.
A parsimonious working model (Fig. 7) of a mechanistic
pathway for miR-22 antagomir-mediated BP reduction proposes
a primary effect in the brainstem to increase Chga protein
(without effect on brainstem Chga mRNA abundance), which
would decrease sympathetic outflow to the periphery (and there-
fore lead to reduced adrenal Chga protein and catecholamine
levels), and, ultimately, lower BP. Indeed, we observed signifi-
cantly reduced adrenal mRNA abundance across the catechol-
amine biosynthetic pathway: Creb1, Th, Dbh and Pnmt
expression decreased after the antagomir. The action of
miR-22 is unlikely to be entirely specific for Chga, and the
role of additional miR-22 targets [such as estrogen receptor
alpha (44) or phosphatase and tensin homolog (45)] in reducing
BP in vivo may prompt further investigation.
The miR-22 motif in the Chga mRNA 3′-UTR is broadly con-
served across species: mouse, rat and human (Fig. 6D), suggest-
ing that inhibition of miR-22 might constitute a viable
therapeutic target even in human hypertension. Genetic vari-
ation at the human miR-22 locus has been associated with
panic disorder and miR-22 regulates several anxiety candidate
genes (46), suggesting broader applications for miR-22
therapy acting through reduction in sympathetic activity. Lack
of adverse effects of miR-22 antagomir on general metabolism
in the SHR (as indexed by the chemistry panel) is an initial indi-
cator of the safety of miR-22 antagomir therapy (Table 5);
however, additional investigations into potential oncogenic
functions of miR-22 (47,48) may be indicated.
CONCLUSIONS AND PERSPECTIVES
Chromogranin A has been implicated in both the heritability (6)
and pathogenesis of human essential hypertension (9), leading us
to probe the Chga locus in the SHR, the most widely studied
animal model of genetic hypertension. Human CHGA 3′-UTR
and promoter polymorphisms that showed association with es-
sential hypertension (8–10) were not directly homologous to
promoter and 3′-UTR polymorphisms located in the SHR
Chga locus. Nonetheless, existence of functional Chga poly-
morphisms in both human essential hypertension and the SHR
Figure 7. Hypothetical schema illustrating the contribution of the Chga 3′-UTR
G + 174T polymorphism to the pathogenesis of hypertension in the SHR. The
Chga 3′-UTR SNP (G + 174T) increases binding of miR-22 to the SHR Chga
mRNA transcript, which decreases Chga protein abundance in the brainstem
(with no change in the Chga mRNA level) and initiates a cascade of events
that increase blood pressure. The effect of treatment with miR-22 antagomir is
to reduce binding of miR-22 to the Chga 3-UTR, which increases the abundance
of Chga protein in the brainstem (without change in Chga mRNA) and, ultimate-
ly, leads to reduction in blood pressure.
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model argues for the pertinence of Chga in the SHR for diagnos-
tic or pathophysiological insights in the human disease. Add-
itional experiments, such as generation of congenic strains
wherein the hypertensive and normotensive Chga loci are inter-
changed across strains, might further buttress a genetic role for
Chga in the pathogenesis of hypertension in the SHR. As
novel genetic associations are established with hypertension,
identification of precise functional variants and elucidation of
their molecular mechanisms will become even more important
in understanding disease pathophysiology. Substantial reduc-
tion in BP in the SHR after miR-22 antagomir highlights a
novel potential avenue for treatment of hypertension.
MATERIALS AND METHODS
Rat strains
Animal studies were performed with age-matched, adult (12–17
weeks) male SHR and WKY rat strains from Charles River La-
boratories (Wilmington, MA. USA). Rats were studied accord-
ing to a protocol approved by the Animal Subjects Committee
of the University of California at San Diego, and research was
conducted in accordance with institutional guidelines.
Transcripts by quantitative real-time polymerase chain
reaction (qRT–PCR)
Isoflurane was used for terminal anesthesia of SHR and WKY
rats. Adrenal glands, brainstem and whole blood (centrifuged
to collect plasma) were isolated from each rat, immediately
frozen in liquid nitrogen, then stored at 2808C. Total RNA ex-
traction and quantitative RT–PCR experiments were performed
by the Animal Clinical Chemistry and Gene Expression Labora-
tory at the University of North Carolina (Chapel Hill, NC, USA).
Total RNA was extracted using the Applied Biosystems (ABI)
6700 automated nucleic acid workstation and quantitative
RT–PCR was performed on mRNA  cDNA with the ABI-
7700, as previously described (49). Cycle threshold (Ct) values
were used to calculate the amount of amplified PCR product. Mes-
senger RNAs were normalized to beta-actin mRNA, while
microRNAs were normalized to either beta-actin mRNA or to
snoRNA-U61 (SNORD61) small nucleolar RNA. Data were
analyzed with Student’s t-test.
Chromogranin A protein assay
Frozen adrenal glands and brainstem were homogenized in
10 mM TRIS (pH ¼ 7.0) buffer (at 48C) and then centrifuged
at 13 000 G (at 48C) for 1 min to clear debris. The supernatant
was retained for immunoassays. Measurement of chromogranin
A protein in the adrenal gland, brainstem and plasma was
performed with a rat enzyme immunoassay kit (epitope:
Arg-Ser-Met-Arg-Leu-Ser-Phe-Arg-Ala-Arg-Gly-Tyr-Gly-Ph-
e-Arg-Asp-Pro-Gly-Leu-Gln-Leu; Cat. # EK-053-29, Phoenix
Pharmaceuticals, Inc., Burlingame, CA, USA). Tissue protein
concentration was determined using the Bio-Rad Protein
Assay (coomassie blue dye absorbance shift; based on the Brad-
ford method) (Bio-Rad, Hercules, CA, USA). In some experi-
ments, we measured adrenal Chga by radiommunoassay based
on the epitope CHGA324 – 337 (or ‘WE-14’) (50). Data were ana-
lyzed with Student’s t-test.
Systematic polymorphism discovery by re-sequencing rat
chromogranin A
The nucleotide sequences of the chromogranin A locus (Chga) in
the SHR, WKY or BN rat strains were determined by capillary
(Sanger dideoxy) re-sequencing with an Applied Biosystems
ABI-3100 Genetic Analyzer, as previously described (51), and
directly aligned with the Brown Norway (BN) reference se-
quence at NCBI. Primers are listed in Supplementary Material,
Table S1. Polymorphisms were identified and visually con-
firmed in the raw sequencing data using the EditView 1.0.1 soft-
ware for Macintosh OS-9 (Applied Biosystems).
Computational prediction of transcription factor
and microRNA binding
Predictions for transcription factors that bind the Chga promoter
regions harboring polymorphisms were made with ConSite (http
:/www.phylofoot.org/consite) (52), a tool for identification of
cis-regulatory elements in genomic sequences. Predictions for
microRNAs that hybridize the Chga 3′-UTR region containing
polymorphisms were performed with MicroInspector (http
://bioinfo.uni-plovdiv.bg/microinspector) (53), a tool for detec-
tion of microRNA binding sites within RNA sequences. Tar-
getScan (http://www.targetscan.org) (54) was used to predict
potential target transcripts for miR-22.
Construction of promoter and 3′-UTR luciferase reporter
plasmids
The following PCR primers were used to amplify a 1.8 kb
Chga proximal promoter fragment from SHR and WKY
genomic DNA: 5′-TAAAGGTACCAGCACACCTAAACTG
TGAC-3′ (forward primer; KpnI site underlined) and 5′-GAG
CAAGCTTGTGCGGAAAGAGAG-3′ (reverse primer;
HindIII site underlined). The promoter fragment was inserted
between KpnI and HindIII sites in the pGL3-Basic vector
(Promega), which lacks eukaryotic promoter and enhancer
sequences, and contains the cDNA for firefly luciferase. The fol-
lowing PCR primers were used to amplify the 333 bp Chga
3′-UTR from SHR and WKY genomic DNA: 5′-ACGGG
CTAGCGGCACTGGCTGGTGGGGTCCGGCCA-3′ (forward
primer; NheI site underlined) and 5′-AAAGGCTAGCGAAG
AGCCCAAAGCAGGTTTATTCT-3′ (reverse primer; NheI
site underlined). The 3′-UTR was inserted into the XbaI site of
the pGL3-Promoter vector (Promega), just downstream (3′) of
the cDNA for firefly luciferase driven by the SV40 promoter.
Correct insertion and orientation of Chga promoter and 3′-UTR
was confirmed by DNA sequencing. Plasmid DNA for transfec-
tion was prepared and purified with the QIAfilter Plasmid Midi
Kit (Qiagen).
Chga promoter and 3′-UTR luciferase reporter transfection
and activity assays
The rat pheochromocytoma cell line PC12, and the human
neuroblastoma cell line SH-SY5Y, were grown and transfected
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with TransFectin (Bio-Rad) (for SH-SY5Y experiments), Super-
fect (Qiagen) (for PC12 promoter–reporter experiments) or
DharmaFECT Duo (Dharmacon) (for PC12 3′-UTR-reporter
experiments) using established protocols.
Promoter-luciferase reporter experiments were performed
with co-transfection of Chga promoter-luciferase reporter
plasmid DNA and mammalian cDNA expression plasmid
DNA (pCMV-promoter; into SH-SY5Y cells: 24-well plates,
250 ng reporter plasmid DNA; into PC12 cells: 12-well plates,
1 mg reporter DNA, 50 ng expression plasmid DNA) for the fol-
lowing transcription factors: pcDNA3.1(-) (empty vector, nega-
tive control; Invitrogen, Carlsbad, CA, USA), E2f1 (Mus
musculus; MMM1013-9201426, Open Biosystems, Huntsville,
AL, USA), Foxd3 (Xenopus tropicalis; MXT1765-98077348,
Open Biosystems), Foxi1 (Mus musculus; MMM1013-64167,
Open Biosystems), HAND1 (Homo sapiens; SC122690,
OriGene, Rockville, MD, USA), Irf1 (Rattus norvegicus;
MRN1768-9510505, Open Biosystems), MYCN (Homo
sapiens; MHS1010-57504, Open Biosystems), PBX1 (Homo
sapiens; MHS4768-99609490, Open Biosystems), Creb1 (Mus
musculus; MMM1013-98477947, Open Biosystems), Sox17
(Danio rerio; MDR1734-97029554, Open Biosystems) and Bra-
chyury (Mus musculus; MMM1013-99829478, Open Biosys-
tems). Cells co-transfected with transcription factor plasmids
were harvested and lysed 20–24 h after transfection for the re-
porter assay.
3′-UTR-luciferase reporter experiments were performed with
co-transfected Chga 3′-UTR-luciferase reporter plasmid DNA
(PC12 cells: 24-well plates; 250 ng reporter plasmid DNA),
and synthetic microRNA precursor (PC12 cells: 30 nM) for
either rno-miR-22 (PM10203, Ambion), rno-miR-320
(PM11621, Ambion) or negative control (CN-001000-01-05,
Dharmacon). Cells co-transfected with microRNAs were incu-
bated for 24–48 h before harvest for reporter activity.
After transfection and subsequent incubation, cells were
treated with lysis buffer (300 ml per well in 12-well plates;
125 ml per well in 24-well plates) [0.1 M phosphate buffer
(K2HPO4 + KH2PO4) (pH 7.8), 1 mM DTT and 0.1% Triton-X
100]. The bioluminescent activity of luciferase in 50 ml of cell
lysate was determined using the AutoLumat LB 953 lumin-
ometer (EG&G Berthold, Nashua, NH, USA) to measure light
emission (incubation time ¼ 0 s, measure time ¼ 10 s,
temperature ¼ 258C) after the addition of assay buffer [100 ml
per sample; 100 mM Tris–acetate (pH 7.8), 10 mM Mg-acetate,
1 mM EDTA (pH 8.0), 3 mM ATP and 100 mM luciferin
(Sigma-Aldrich)]. As an internal control for varying cell
number in each well, the total protein content was measured in
cell lysate using the Bio-Rad Protein Assay (coomassie blue dye
absorbance shift; based on the Bradford method) (Bio-Rad, Her-
cules,CA,USA).Luciferaseactivitywas expressed as the normal-
ized ratio of (relative light unit)/(total protein) or (RLU/mg
protein). Data were analyzed with analysis-of-variance
(ANOVA), followed by pair wise t-tests corrected for multiple
comparisons (Bonferroni). Significance of genotype–transcrip-
tion factor interaction and genotype–microRNA interaction was
assessed with two-way ANOVA (dependent variable ¼ lucifer-
ase activity; two independent variables ¼ genotype and transcrip-
tion factor/microRNA).
Chga cDNA/EAP chimera reporter plasmid construction
and EAP secretion and activity assay
The following PCR primers were used to amplify the 1389 bp rat
Chga cDNA from a Norway rat (Rattus norvegicus) cDNA clone
(NCBI GenBank accession: NM_021655):
5′-ATGCCTCGAGGCCACCATGCGCTCCTCCGCGGC-
TTTGG-3′ (forward primer; XhoI site underlined; Kozak se-
quence in bold; translation start site underlined) and
5′-ATGCGGTACCCTCCCCGTCGCTAAGCCTGCAG-3′ (re-
verse primer; KpnI site underlined). The amplified Chga cDNA
was inserted between XhoI and KpnI sites in an EAP chemilumin-
escent reporter vector, pEAP-N2, which contains the CMV pro-
moter and a truncated domain (EAP) of full-length human
secreted embryonic alkaline phosphatase (55). The BN rat
Chga cDNA sequence was identical to the WKY Chga cDNA se-
quence. The SHR Chga cDNA-EAP reporter was constructed by
PCR amplifying the WKY cDNA-EAP construct with mutagen-
esis primers (designed todeleteeight glutamine residues or 24 bp)
[5′-AAAGAGGAAGAGGAGGAGGAGAAAGAGGAGAAGG
CGATCGCCAGAGAGAAGGCT-3′ (forward primer) and 5′-C
TCCTCCTCTTCCTCTTTCTCCTCTTGCTTGGCTTTTCTGG
CTTGCTGCTGGGCACTGGGACC-3′, reverse primer)], treat-
ing the PCR product with DpnI to digest WKY template DNA,
and then ligating the linear SHR PCR product with the Rapid
DNA Ligation Kit (Roche, Indianapolis, IN, USA). Sequence of
the SHR and WKY Chga cDNA was confirmed by DNA sequen-
cing(ABI3100).PlasmidDNA waspreparedandpurified for trans-
fection with the QIAfilter Plasmid Midi Kit (Qiagen).
Rat PC12 pheochromocytoma cells (from ATCC) [grown in
F-12K (Invitrogen) with 2.5% heat-inactivated fetal bovine
serum (Gemini Bioproducts, Woodland, CA, USA), 15%
heat-inactivated horse serum (Gemini Bioproducts), penicillin
(100 U/ml), streptomycin (100 mg/ml) and L-glutamine
(0.292 mg/ml)] were transfected (at 50% confluence, 1 day
after splitting 1:3) with Chga cDNA/EAP reporter plasmid
DNA [SHR or WKY; 2.5 mg supercoiled DNA per well;
6-well polystyrene plates (coated with poly-L-lysine (Sigma)
and rat collagen (Upstate)), 3.48-cm diameter wells, Corning
Inc., Corning, NY] using the GenePorter2 Transfection
Reagent (cationic lipid, Genlantis, San Diego, CA). After trans-
fection, cells were incubated for 30 h to allow sufficient time for
the Chga-EAP chimera to be transcribed, translated, and shuttled
through the Golgi into regulated secretory granules.
Two hours before performing the EAP secretion activity
assays, the cells were incubated with tritiated norepinephrine
(3H-NE; 0.5 mCi per 1 ml cell media). The assay was performed
by stimulating the cells with 700ml of calcium secretion buffer (a
negative control; 150 mM NaCl, 5 mM KCl, 2 mM CaCl2, 10 mM
HEPES pH 7.4) or barium secretion buffer (a potent exocytotic
secretory stimulus; 150 mM NaCl, 5 mM KCl, 2 mM BaCl2,
10 mM HEPES pH 7.4), and collecting cellular supernatant and
lysate fractions after a 15-min secretory incubation. Tritiated
norepinephrine (read for 2 min) and chemiluminescent EAP ac-
tivity (read for 10 s) were measured in both cell supernatant and
cell lysate fractions (Phospha-Light System, Applied Biosys-
tems). Final EAP activity is expressed as the normalized ratio
of (EAP activity)/(3H-NE counts per minute) or (RLU/cpm),
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and was used to compute ‘relative secretion’ and ‘sorting
index.’ We previously described EAP activity assays in add-
itional detail (56).
Rs is defined as the fraction of total EAP activity that is found
in the supernatant: Rs ¼ (EAP activity in supernatant)/(EAP ac-
tivity in supernatant + EAP activity in lysate). SI is defined as
the difference between Rs of barium- and calcium-treated cells
normalized by the Rs of calcium treated cells: SI ¼ (Rsbarium –
Rscalcium)/Rscalcium.
Chga sequence conservation and coiled-coil prediction
Conservation of the Chga locus sequence across rat, mouse, dog,
rhesus and human was determined with the VISTA browser (http
://pipeline.lbl.gov/cgi-bin/gateway2) (57). Conservation of spe-
cific Chga protein domains across mammals (Homo sapiens,
Macaca mulatta, Bos taurus, Canis familiaris, Equus caballus,
Mus musculus and Rattus norvegicus) was determined by Clus-
talW alignment of the protein sequence downloaded from the
University of California, Santa Cruz, genome browser (http
://genome.ucsc.edu) (58).
The probability of SHR and WKY Chga protein to assume a
3D coiled-coil conformation was computed with the COILS al-
gorithm (http://www.ch.embnet.org/software/COILS_form.
html) (59). In brief, the algorithm searches for strongly amphi-
pathic regions that display a pattern of alternating hydrophilic
and hydrophobic residues repeated every seven residues
(heptad repeat residues a g, with a and d being hydrophobic).
The minimum window was two such heptads, over 14 residues.
The probability of coiled-coil structure is presented as a function
of amino acid position in the mature Chga protein.
Inhibition of microRNA-22 by synthetic antagomir in vivo
Male SHR age 10–11 weeks, weight 210–240 g; from Charles
River) were administered either a negative control (n ¼ 9)
[LNA (‘locked’ nucleic acid) oligonucleotide scrambled se-
quence with phosphorothioate backbone: 5′-ACGTCTATACG
CCCA-3′; Exiqon, Woburn, MA, USA] or rno-miR-22 antago-
mir (n ¼ 10) (LNA oligonucleotide with phosphorothioate
backbone: 5′-CTTCAACTGGCAGCT-3′; Exiqon). Oligonu-
cleotides were delivered via i.p. injection (every other day for
a total of four injections; Days 1, 3, 5 and 7) at a dose of
25 mg/kg body weight. Blood pressure measurement preceded
antagomir administration by 1–2 h each day to allow a recovery
period. We used the CODA high-throughput rodent tail-cuff
system (Kent Scientific; Torrington, CT, USA) to measure BP
1 time per day (average of 20 readings in 1 session) on Days 1,
3, 5, 7 and 9. Pentobarbital sodium (‘Fatal-Plus’) was used for
terminal anesthesia of rats after four doses (9 days) of miR-22
antagomir or negative control. Adrenal glands, brainstem and
whole blood (which was centrifuged to collect plasma) were iso-
lated from each rat, immediately frozen in liquid nitrogen, then
stored at 2808C. Quantitative real-time polymerase chain reac-
tion (qRT–PCR) and chromogranin A protein immunoassay
(Cat. # EK-053-29, Phoenix Pharmaceuticals, Inc.) were per-
formed as described above. A linear mixed effects model for
fixed effects (implemented in SPSS-17 for Mac OS-X) was
used to test for the effect of treatment (negative control versus
miR-22 antagomir) on SBP, DBP and HR. Data are presented
as mean+SEM.
Blood chemistry panel during miR antagomir treatment
We performed a chemistry panel on the plasma from SHR treated
with negative control or miR-22 antagomir. We assayed glucose,
BUN, creatinine, sodium, phosphorus, alkaline phosphatase,
albumin, serum glutamic pyruvic transaminase (SGPT), total
protein, globulin, total bilirubin and amylase using the VetScan
VS2 comprehensive diagnostic profile (#500–1038; Abaxis,
Union City, CA, USA). Data were analyzed with Student’s t-test.
Linkage and correlation analysis of Chga in rat RI strains
Linkage analysis was performed in the HXB/BXH RI set of rat
strains derived from SHR and BN progenitor strains (60), as pre-
viously described (61). Experiments were performed in 29 RI
strains (HXB and BXH at .F60) in accordance with the
Animal Protection Law of the Czech Republic (311/1997) and
were approved by the Ethics Committee of the Institute of Physi-
ology, Czech Academy of Sciences, Prague. Animals were male
and age matched at 6 weeks.
Adrenal glands were harvested, immediately frozen and stored
at 2808C. One adrenal gland per animal was used for Chga
protein quantification, whereas the other was used for mRNA ex-
traction, as previously described (61).Adrenal glands for the Chga
protein assay were homogenized in 1.9 ml of 10 mM MES buffer
(pH ¼ 6.0) with a Tissuemizer (Tekmar, Cincinnati, OH, USA),
and then spun at 13 000g for 1 min to clear debris. Supernatants
were saved, divided into aliquots and placed immediately on
dry-ice to freeze. Chga protein was quantified in RI strain
adrenal glands with a radioimmunoassay that recognized rat
Chga. Radioimmunoassay results were normalized to wet tissue
weight or milligram protein.
We used a SNP genotype-based linkage map (62), and the
QTL Cartographer (63) and Map Manager QTX (64) software
packages to detect the presence of QTLs for adrenal Chga
protein across the rat genome. Permutation analyses (65) were
used to compute the probabilistic significance of linkage and
to correct P-values for genome-wide multiple testing. The
two-LOD support interval method (66) and the bootstrap test
(67) were implemented to estimate the 95% confidence interval
for the size of chromosomal segments containing QTLs, as pre-
viously described (61). The LOD score significance was esti-
mated as described by Nyholt (23), with the calculator
available at ,http://genepi.qimr.edu.au/general/daleN/..
We searched the online data repository at ,www.
genenetwork.org. (68) (where our RI strain adrenal biochem-
ical phenotypes are deposited) for evidence of meiotic linkage
for Chga protein (adrenal) in the HXB/BXH RI strains. We
also computed Pearson correlations between adrenal Chga
protein and biochemical hypertensive disease traits using the
statistical tools available at ,www.genenetwork.org..
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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